Raymond James & Associates Paratek Pharmaceuticals, Inc. Call Options Transaction History

Raymond James & Associates

  • $150 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2021

Nov 02, 2021
SELL
$4.7 - $7.24 $51,700 - $79,640
-11,000 Closed
0 $0
Q2 2021

Aug 11, 2021
SELL
$6.81 - $10.93 $74,910 - $120,230
-11,000 Reduced 50.0%
11,000 $2,000
Q3 2020

Nov 04, 2020
BUY
$4.19 - $6.69 $92,180 - $147,180
22,000 New
22,000 $51,000

Others Institutions Holding PRTK

# of Institutions
4
Shares Held
1.54M
Call Options Held
0
Put Options Held
0
View Full List

About Paratek Pharmaceuticals, Inc.

PRTK Quotes by TradingView
  • Ticker PRTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,862,500
  • Description
  • Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...
More about PRTK
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email